News & Updates

Evaluation and treatment rates of patients with chronic hepatitis B (CHB) remain poor worldwide and differ by sex and race or ethnicity, reports a real-world study.

In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).

Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.

Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.

The inclusion of remdesivir in the SoC is significantly associated with a 54-percent lower risk of death at day 28 among hospitalized adults with COVID-19 who require O₂ support, suggests a cross-study comparison that weight-balances patients from a clinical trial with those from a real-world study